Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 03, 2023

BUY
$22.82 - $35.32 $2,578 - $3,991
113 Added 168.66%
180 $4,000
Q4 2022

Feb 06, 2023

BUY
$25.35 - $31.96 $1,698 - $2,141
67 New
67 $2,000
Q2 2022

Jul 19, 2022

SELL
$20.62 - $37.15 $3,072 - $5,535
-149 Closed
0 $0
Q1 2022

Apr 29, 2022

BUY
$23.5 - $35.38 $3,501 - $5,271
149 New
149 $5,000
Q4 2021

Jan 24, 2022

SELL
$29.21 - $44.64 $3,037 - $4,642
-104 Closed
0 $0
Q3 2021

Oct 29, 2021

BUY
$21.26 - $38.85 $2,211 - $4,040
104 New
104 $3,000

Others Institutions Holding CERE

About Cerevel Therapeutics Holdings, Inc.


  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Tci Wealth Advisors, Inc. Portfolio

Follow Tci Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.